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Introduction
viruses infect organisms from all domains of life. The 
evolutionary pressure they exert on their hosts is evident 
from the presence of a multitude of defence mechanisms. 
examples for strategies of how different organisms ensure 
immunity to virus infection include the CRISPR system in 
bacteria [1] or RNA interference in plants and invertebrates 
[2, 3]. Perhaps not surprisingly, viruses evade and coun-
teract such antiviral mechanisms, and this in turn results 
in the emergence of new host defence pathways. Indeed, 
higher organisms typically employ a variety of measures 
to contain and eliminate infecting viruses. For example, 
in mammals, cytotoxic T-cells, antibodies, natural killer 
cells, interferons and a variety of antiviral proteins all con-
tribute to the immune response that ensues following virus 
infection.
This review focuses on virus restriction factors. Most 
definitions of the term agree that a restriction factor is a 
host protein that directly inhibits a stage in the life cycle of 
a virus in a cell-intrinsic manner. In other words, restriction 
factors need to be present in an infected cell and typically 
counteract infection in that cell or in some cases are trans-
ferred to the next target cell. Here, I will use this definition, 
although additional criteria are sometimes applied [4, 5]. 
Indeed, restriction factors are often under positive selec-
tion and are typically targeted by viral antagonists, reflect-
ing the evolutionary arms race between virus and host. 
Further, the expression of mammalian restriction factors is 
often induced by cytokines such as the type I interferons, 
important mediators of antiviral immunity. Some restriction 
factors are highly specific and control only a narrow range 
of viruses, whereas other restriction factors broadly target 
several classes of viruses. Proteins such as pattern-recogni-
tion receptors that are involved in detecting the presence of 
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ciency virus 1 (HIv-1) is controlled by restriction fac-
tors, host proteins that counteract a variety of steps in 
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viruses and in inducing an antiviral state are typically not 
considered to be restriction factors. Instead, restriction fac-
tors are characterised by direct modes of action against the 
life cycle of a virus. In principle, the concept of restriction 
factors is applicable to any virus and host. However, the 
term was initially coined and is still most commonly used 
in the context of mammalian retrovirus infection.
The importance of studying restriction factors in vivo
Restriction factors are often studied in experiments using 
cultured cells. Their overexpression is predicted to inhibit 
virus replication, while their loss-of-function is presumed 
to have the opposite outcome enhancing virus replication. 
Indeed, such effects are typically taken as evidence that a 
protein is a virus restriction factor. Biochemical and struc-
tural analyses often provide mechanistic insight into how 
a restriction factor antagonises virus infection and pinpoint 
the step in the virus life cycle that is targeted. Collectively, 
data from these types of in vitro studies are immensely 
valuable in identifying and characterising proteins that can 
restrict viruses. Moreover, the mechanistic data generated 
by in vitro studies often suggest new avenues for therapeu-
tic antiviral interventions.
A full understanding of the biology of restriction factors, 
however, can only be obtained if in vitro data are comple-
mented by in vivo experiments, testing the role of a restric-
tion factor in a living organism. Indeed, how restriction fac-
tors contribute to immunity of the host to virus infection 
can only be investigated in vivo, given the complexity of 
the antiviral immune response. Small animal models can 
be used as a tool to dissect the contribution of restriction 
factors to antiviral immunity in vivo, and several restriction 
factors have been genetically ablated in the mouse. virus 
challenge experiments in such knockout mice have begun 
to reveal how restriction factors contribute to the control of 
viruses at an organismal/systemic level and have provided a 
number of surprising insights into the biology of restriction 
factors.
Restriction factors targeting retroviruses
Retroviruses are a large family of diverse viruses. Sub-
families include the beta- and gamma-retroviruses, typified 
by murine mammary tumour virus (MMTv) and murine 
leukaemia virus (MLv), respectively, and the more com-
plex lentiviruses such as human immunodeficiency virus 
1 (HIv-1). Retrovirus particles are enveloped by a lipid 
bilayer membrane derived from host cells and contain an 
RNA genome. viral proteins present in the virion include 
reverse transcriptase, integrase, structural proteins form-
ing a capsid around the RNA genome and transmembrane 
glycoproteins. The latter mediate attachment to target cells 
and facilitate entry via fusion of the viral envelope with cel-
lular membranes. As a result, the viral RNA genome and 
associated proteins enter the cytosol of infected cells. In 
addition to viral proteins, some cellular proteins such as 
APOBeC3G (see below) can also be packaged into viri-
ons and delivered into new target cells. Next, reverse tran-
scriptase converts the RNA genome into complementary 
DNA (cDNA), which is then integrated into the genome of 
the infected cell. Lentiviruses transport the viral pre-inte-
gration complex, containing cDNA and integrase, across 
nuclear pores and are, therefore, able to infect quiescent, 
non-dividing cells. In contrast, many other retroviruses 
depend on the breakdown of the nuclear envelope during 
mitosis to gain access to the host genome and only infect 
dividing cells. The next step in the life cycle of retroviruses 
is transcription of the integrated proviral DNA into viral 
messenger RNA. viral proteins are translated and assemble 
new virions together with two copies of the RNA genome 
transcribed from the provirus. Last, progeny virus particles 
bud from the cell membrane, which in some cases is fol-
lowed by a maturation step of the virion.
Many of these steps of the retroviral life cycle are tar-
geted by restriction factors. Figure 1 summarises some of 
the currently known HIv-1 restriction factors in the context 
of the infection cycle. In the next sections, selected HIv-1 
restriction factors are discussed and data from mouse 
knockout models are summarised. Mice are not the natural 
hosts of HIv-1 and a number of blocks to infection exist 
in rodent cells [6]. Nevertheless, several HIv-1 restriction 
factors are conserved between human and mouse (Table 1). 
Moreover, some aspects of the HIv-1 life cycle can be 
studied in murine models, for example by circumventing a 
block to entry by pseudotyping viral particles with vesicu-
lar stomatitis virus glycoprotein (vSv-G). It is, therefore, 
possible to characterise at least some of the functions of 
these proteins during HIv-1 infection by genetic ablation 
in the mouse. In addition, mice are naturally infected by a 
number of beta- and gamma-retroviruses, and in vivo infec-
tions of knockout mice with these viruses have provided 
new insights into the biology of restriction factors, some of 
which can perhaps be extrapolated to HIv-1.
It is noteworthy that the very concept of virus restriction 
is based on observations made in murine models of retrovi-
rus infection [7, 8]. work carried out almost 50 years ago 
discovered that certain inbred strains of mice are sensitive 
to infection with Friend virus, whereas others are not [9, 
10]. Friend virus is a mix of a replication-competent helper 
virus and a replication-defective transforming virus and 
is a model for gamma-retrovirus infection. Friend virus 
causes erythroleukaemia in susceptible strains of mice. 
Crosses between resistant and susceptible strains revealed 
that resistance is inherited in a dominant way. Mapping of 
the genes underlying the resistance phenotype led to the 
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discovery of some of the first restriction factors [11, 12]. 
One of these, encoded by the Fv4 gene, restricts MLv 
infection by a mechanism called receptor interference. The 
Fv4 protein blocks access of the envelope glycoprotein of 
the infecting virus to its cognate receptor [7, 13]. Fv4 is 
derived from an endogenous retrovirus. It is related to the 
MLv envelope glycoprotein, but—due to mutations—Fv4 
is non-functional as a viral envelope glycoprotein. Nev-
ertheless, it is still able to interact with and mask cellular 
receptors required for MLv uptake, thereby preventing 
infection with exogenous virus. Another restriction fac-
tor uncovered by these experiments in mice is encoded by 
the Fv1 gene. As for Fv4, the Fv1 gene is derived from an 
endogenous retrovirus. It encodes a protein related to the 
capsid protein of exogenous retroviruses [14]. Indeed, the 
Fv1 gene product targets the capsids of incoming viruses 
and appears to interfere with their subcellular trafficking 
[14].
These studies of retrovirus restriction in mice paved 
the way for the discovery of many more restriction factors 
controlling a variety of viruses, including some important 
human pathogens. This review discusses selected restric-
tion factors that counteract HIv-1, with a focus on what has 
been learned from recent mouse knockout models.
Restriction of HIV‑1 at the membrane
Fusion of the viral envelope to cellular membranes as well 
as budding of progeny virus particles from the plasma 
membrane are key steps in the retroviral life cycle. Both are 
targeted by restriction factors.
As discussed earlier, the Fv4 gene controls MLv infec-
tion in mice by blocking the interaction of the virus with 
its receptor on host cells [7, 13]. whether lentiviruses 
such HIv-1 are restricted by a similar pathway—i.e. 
expression of an envelope-mimic from an endogenous 
retrovirus—is unknown. Nevertheless, recent data suggest 
that entry of HIv-1 is indeed inhibited by host factors, 
namely the interferon inducible transmembrane (IFITM) 
proteins. The IFITMs are a family of small proteins with 
two transmembrane domains and are involved in cell 
adhesion, cell proliferation, development, bone formation 
and host–pathogen interactions [15–18]. The expression 
of three IFITM proteins, IFITM1-3, is induced by type I 
interferons, suggestive of an antiviral function. Indeed, 
RNA interference screening identified a role for IFITM1-3 
in controlling RNA virus infection [19]. An overexpres-
sion screen of interferon-stimulated genes revealed that 
IFITM3 and perhaps IFITM2 can control HIv-1 [20]. 
Further in vitro studies using overexpression of IFITM1-3 
and depletion of these proteins by RNA interference 
substantiated the evidence that these proteins are HIv-1 
restriction factors [21–23]. Consistent with the notion that 
IFITM3 restricts RNA virus infection by blocking fusion 
[24, 25], it is believed that IFITM3 and IFITM2 proteins 
also inhibit fusion of HIv-1 [21, 22]. It is possible that the 
role of IFITM proteins in controlling HIv-1 depends on 
cell type and that these proteins restrict the virus by mul-
tiple mechanisms [18, 22, 23]. For example, IFITM1 has 
been suggested to restrict HIv-1 after entry [22]. These 
are important questions for future work and it will also be 
interesting to challenge mice lacking IFITM proteins with 
retroviruses to determine the in vivo relevance of these 
factors to anti-retroviral defence. whether retroviruses 
encode IFITM antagonists is another interesting issue for 
future studies.
Fig. 1  HIv-1 restriction factors. The function of selected HIv-1 
restriction factors is shown in the context of the HIv-1 life cycle. 
Restriction factors are indicated in black and steps in the viral life 
cycle are in red. viral proteins are represented by coloured symbols, 
including reverse transcriptase (violet squares), integrase (green tri-
angles) and envelope glycoprotein (orange hexagons). viral RNA is 
represented by a wavy red line and viral DNA by a straight dark blue 
line. The functions of MOv10, Mx2 and viperin are speculative as 
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Not only entry of retroviruses into host cells but 
also their egress following successful genome replica-
tion is controlled by restriction factors. One example is 
2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP) that 
has recently been shown to be involved in counteracting 
assembly of progeny virions. CNP is associated with the 
cell membrane, is encoded by an interferon stimulated gene 
and inhibits a late stage in assembly of HIv-1 progeny viri-
ons [26]. Mechanistically, it has been proposed that CNP 
blocks assembly after the structural protein Gag and viral 
RNA have associated with the plasma membrane and that 
it interacts with Gag [26]. Mouse CNP is unable to control 
HIv-1 particle production in overexpression settings [26]. 
It will be interesting to determine if mouse CNP controls 
MLv and other mouse retroviruses, and to determine if and 
how it shapes virus infections in vivo.
viperin (also known as CIG5 and RSAD2) is another 
protein that may restrict egress of HIv-1. viperin is a 
transmembrane protein encoded by an interferon stimu-
lated gene and localises to the endoplasmic reticulum [27, 
28]. An antiviral function against a variety of viruses has 
been demonstrated, but the mechanisms by which viperin 
exerts these effects are not fully understood [27, 28]. One 
possible antiviral mechanism by which viperin may con-
trol budding of enveloped viruses is modification of the 
lipid environment within the cell [27, 28]. viperin has 
been proposed to control HIv-1 in vitro [29–31], although 
some of the inhibitory effect might be virus strain and/or 
cell type specific [29]. viperin-deficient mice are avail-
able [32, 33], but have not been tested in in vivo retrovirus 
infection models.
The most intensely studied host protein restricting HIv-1 
at the membrane is tetherin (also known as BST-2, CD317, 
HM1.24 and PDCA-1). Its function is antagonised by 
the HIv-1 accessory protein vpu. In fact, the observation 
that vpu-deficient viruses are released inefficiently from 
infected cells led to the discovery of tetherin as a restric-
tion factor in 2008 [34, 35]. Tetherin is a dimeric type II 
transmembrane protein bearing a short N-terminal cyto-
plasmic tail, followed by a transmembrane domain, a long 
α-helical region and a C-terminal glycophosphatidylinosi-
tol (GPI) membrane anchor [36]. As such, tetherin inserts 
into membranes twice with both its N- and C-terminus, 
and this explains its antiviral activity: tetherin connects or 
“tethers” the cell membrane to the envelope of newly bud-
ded virus particles and this prevents virus release from the 
cell [34–36]. Tetherin can bridge between the cell and the 
virus in two different configurations: the transmembrane 
domain can be inserted either into the cell membrane or 
into the viral envelope (Fig. 2). In the former case, the GPI 
anchor is inserted into the virus, whereas in the latter case, 
it is found in the cell membrane [36]. HIv-1 vpu antago-
nises tetherin by interfering with its transport to the plasma 
membrane and by re-routing tetherin to a degradative 
compartment [36]. Some other lentiviruses have evolved 
alternative strategies to counteract tetherin involving the 
env and Nef proteins [36]. whilst strong in vitro evidence 
shows that tetherin interferes with the release of free virus 
from infected cells into the surrounding culture medium, 
the protein may actually enhance cell-to-cell spread of 
HIv-1 [37]. This perhaps occurs by concentrating virus at 
the surface of an infected cell [37], although this notion is 
controversial [38, 39].
Two studies tested the in vivo function of tetherin using 
independent lines of knockout mice [40, 41]. Tetherin-
deficient mice are viable and have no easily recognisable 
phenotype. Moreover, the development of lymphocytes and 
other cells of the immune system appears to be unaffected 
in the absence of tetherin [40, 41]. In one study, infection 
of wild-type and tetherin knockout mice with exogenous 
Moloney murine leukaemia virus (M-MLv) resulted in 
identical virus replication and pathogenesis [40]. In the 
other study, splenic M-MLv titres 11 days after infection 
were slightly higher in tetherin-deficient mice than those in 
wild-type control animals, although the difference was not 
statistically significant [41]. Both human and mouse teth-
erin are encoded by type I interferon stimulated genes [36, 
40]. As such, tetherin expression is low at baseline. Moreo-
ver, in vivo M-MLv infection does not induce appreciable 
amounts of type I interferon and does not induce teth-
erin expression, providing an explanation for the lack of 
a clear phenotype in infected tetherin knockout mice [40, 
41]. Consistently, when type I interferons—and as a con-
sequence tetherin—are experimentally induced in vivo by 
administration of poly I:C during an established M-MLv 
infection, viral titres are reduced in wild-type mice but 
not in tetherin-deficient animals [40]. Moreover, another 
Fig. 2  Tetherin prevents release of virus particles from infected 
cells. Tetherin is shown in black with red filling. Tetherin is a type II 
transmembrane protein. The N-terminus is indicated (N) and bears a 
short cytoplasmic tail, followed by a transmembrane domain (TM), a 
coiled-coil region and a C-terminal glycophosphatidylinositol (GPI) 
anchor (circle). During budding, either the TM domain or the GPI 
anchor can be incorporated into virions, resulting in their “tether-
ing” to the plasma membrane. The two different conformations by 
which tetherin can connect the cell membrane with the viral envelope 
are indicated (1 and 2). Please note that tetherin forms a dimer via 
coiled-coil interactions, which is not shown here for simplicity
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strain of MLv (LP-BM5), which naturally induces type I 
interferons, replicated to higher titres and caused increased 
pathology in tetherin knockout mice [40]. Taken together, 
these data from knockout mice suggest that tetherin con-
trols retrovirus infection in vivo—by limiting virus levels 
and pathogenesis—as long as its expression is induced 
by type I interferons. Consistent with this notion, in vivo 
depletion of tetherin by local administration of siRNAs 
enhances MMTv replication [42]. Interestingly, a tetherin 
polymorphism naturally occurring in NZw/LacJ mice trun-
cates the N-terminal cytosolic tail of the protein [43]. As 
a result of this truncation, cell surface expression of teth-
erin is increased compared to C57BL/6 mice that express 
canonical tetherin [43]. In a Friend virus infection model, 
virus replication and pathogenesis inversely correlated with 
tetherin cell surface levels [43], underscoring that tetherin 
is a retrovirus restriction factor not only in vitro but also in 
vivo.
Although tetherin was initially described as an HIv-1 
restriction factor and has been primarily studied in the 
context of retrovirus infection, its mechanism (retain-
ing viral particles at the cell surface by inserting into the 
viral envelope) suggests that tetherin might also target 
other enveloped viruses. Indeed, tetherin limits release 
of herpesviruses [44, 45], filoviruses [46] and flavivi-
ruses [47, 48]. In addition, tetherin has been suggested 
to control influenza A virus [49–52], although some stud-
ies do not agree with this conclusion [53, 54]. The avail-
ability of tetherin-deficient mice opens the exciting pos-
sibility to test if and how this restriction factor controls 
non-retroviral pathogens. Surprisingly, in an initial set of 
experiments, Colonna and colleagues found that while in 
vivo replication of mouse cytomegalovirus (a herpesvi-
rus) was comparable in wild-type and tetherin-deficient 
mice, titres of influenza B virus (an orthomyxovirus) and 
vesicular stomatitis virus (a rhabdovirus) were actually 
reduced in knockout mice [41]. A possible explanation 
is that tetherin may have a function in cellular uptake of 
these viruses. Consistent with this notion, in the case of 
human cytomegalovirus, tetherin appears to be advanta-
geous to the virus by enhancing entry into target cells 
[55]. Other reasons for the decreased replication of some 
viruses in tetherin-deficient mice may relate to a possible 
role of tetherin in type I interferon production by plas-
macytoid dendritic cells and/or in the adaptive immune 
response [41]. Tetherin gene-targeted mice will be key 
tools to study these questions. Another important issue 
that should be addressed in tetherin knockout mice is 
its role as a signalling molecule activating NFκB [36]. 
Indeed, in vitro studies suggest that tetherin acts as a 
virus sensor and induces the expression of proinflamma-
tory genes via NFκB [56–58], but the impact this has in 
vivo is unknown.
Intracellular HIV‑1 restriction before integration
SAMHD1 restricts reverse transcription
After entry of the virus into the cytosol, reverse transcrip-
tion of the retroviral RNA genome occurs. The recently 
identified restriction factor SAMHD1 targets this step in the 
life cycle of HIv-1 [59–61]. The discovery of SAMHD1 as 
a restriction factor goes back to the observation that HIv-1 
infection is inefficient in quiescent myeloid cells such as 
dendritic cells [62–64]. The closely related virus HIv-2 
infects these types of cells much more readily. This differ-
ence between HIv-1 and HIv-2 has been attributed to vpx, 
an accessory protein encoded by HIv-2 but not by HIv-1. 
Indeed, infection of myeloid cells with HIv-1 is markedly 
enhanced in the presence of vpx, which overcomes a post-
entry block prior to or at the level of reverse transcription 
[64–66]. At the time, this suggested that myeloid cells 
express a restriction factor and that vpx inactivates this 
protein, which perhaps interferes with reverse transcription.
Two proteomic studies identified SAMHD1 as a host 
protein co-purifying with vpx [67, 68]. These studies also 
showed that vpx recruits a cellular ubiquitin ligase com-
plex to SAMHD1, targeting the protein for proteasomal 
degradation [67, 68]. As a result, SAMHD1 protein levels 
are greatly reduced in the presence of vpx [67, 68]. Impor-
tantly, depletion of SAMHD1 in myeloid cells by RNA 
interference at least partly phenocopies the effect of vpx 
and facilitates infection with HIv-1-derived lentivectors 
[67, 68]. Taken together, these two landmark papers pub-
lished in 2011 identified SAMHD1 as a new HIv-1 restric-
tion factor [67, 68]. Since then rapid progress has been 
made in characterising in detail how SAMHD1 controls 
infection [59–61].
SAMHD1 has two protein domains: an N-terminal ster-
ile alpha motif (SAM) and a central HD-domain. A vari-
ety of proteins comprise either a SAM- or an HD-domain, 
but SAMHD1 is the only protein described to this date in 
which these two domains are found together. HD-domains 
found in other proteins often mediate phosphohydrolase 
activities [69]. This led to the discovery that SAMHD1 
degrades deoxynucleoside triphosphates (dNTPs), the 
building blocks of DNA [70, 71]. SAMHD1 cleaves all four 
dNTPs, releasing inorganic triphosphate and nucleosides 
[70, 71]. Consistent with these observations, depletion of 
SAMHD1 from cells by vpx delivery, RNA interference or 
genetic ablation results in elevated intracellular dNTP con-
centrations [72–77]. This suggests that SAMHD1 restricts 
HIv-1 by degrading dNTPs, the substrates used by reverse 
transcriptase during cDNA synthesis (Fig. 3a) [78]. This 
mechanism has been variably called “nucleotide embargo” 
or “nucleotide starvation” [60, 79]. Indeed, dNTP con-
centrations in human macrophages—a cell type in which 
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SAMHD1 restriction is very efficient—are lower than the 
KM of HIv-1 reverse transcriptase for dNTPs [72, 80, 81]. 
Importantly, dNTP levels are increased above the KM after 
SAMHD1-depletion in human macrophages [72, 74].
In addition to its function as a dNTP hydrolase, 
SAMHD1 has been described to bind to nucleic acids [82, 
83] and to have nuclease activity [84]. Currently available 
structures of SAMHD1 neither reveal the presence of an 
RNA or DNA binding domain nor of a nuclease domain 
[70, 85, 86]. However, the N-terminus of SAMHD1 con-
taining the SAM domain is lacking from these crystal 
structures and some SAM domains are protein-RNA inter-
action modules [87]. It is, therefore, plausible that full-
length SAMHD1 binds nucleic acids and perhaps has 
nuclease activity. This may explain why some studies 
find that mutant forms of SAMHD1, which have normal 
dNTPase activity, fail to restrict HIv-1 in in vitro overex-
pression settings [88, 89] and that the effect of vpx cannot 
entirely be recapitulated by provision of cells with an excess 
of deoxyribonucleosides [90]. As such, sequestration and/or 
degradation of HIv-1-derived nucleic acids and “dNTP star-
vation” are alternative—although not necessarily mutually 
exclusive—mechanistic explanations for SAMHD1’s activ-
ity blocking reverse transcription (Fig. 3a).
Two studies published in 2013, one by the Roers group 
and one by our laboratories, described independent lines of 
SAMHD1 knockout mice [76, 77]. These animals develop 
normally, are fertile and do not display any obvious abnor-
malities. Both studies show that dNTP levels are increased 
in SAMHD1 knockout cells, providing genetic evidence 
that dNTP hydrolysis is an evolutionarily conserved func-
tion of SAMHD1 [76, 77].
experiments in which these mice were challenged with 
HIv-1 based lentivectors yielded some interesting insights 
into the biology of SAMHD1 [91, 92]. we started by infect-
ing bone marrow derived dendritic cells and macrophages, 
as well as live mice, with vSv-G pseudotyped lentivec-
tors [76]. Unexpectedly, infection levels in wild-type and 
SAMHD1-deficient cells in vitro and in mice in vivo were 
identical [76], in contrast to what had been observed in 
human cells depleted of SAMHD1 and infected with the 
same or very similar lentivectors [67, 68, 72]. Surpris-
ingly, we found the dTTP concentration in mouse dendritic 
cells to be 0.5 μM [76], while human monocyte-derived 
macrophages contain around 0.05 μM dTTP [72, 80, 81]. 
whether this reflects a species difference between humans 
and mice or is simply due to differences in cell type and/
or culture conditions remains to be seen. The KM of HIv-1 
RT for dTTP is approximately 0.07 μM [80]. Therefore, 
a possible explanation for the lack of SAMHD1-depend-
ent restriction in mouse dendritic cells is that dNTP pools 
are not limiting reverse transcription. To test this idea, we 
infected cells and mice with a reverse transcriptase point 
mutant (v148I) lentivector [76]. This mutation increases 
the KM of reverse transcriptase for dNTPs [93]. The infec-
tivity of lentivectors with this mutant reverse transcriptase 
was reduced in wild-type cells and mice [76]. This restric-
tion was relieved by SAMHD1-deficiency, both in vitro 
in different types of cells as well as in vivo [76]. Taken 
together, these results show that SAMHD1 not only con-
trols infection in cultured cells but also in a living organ-
ism. Similar conclusions were drawn from infection experi-
ments performed in the other strain of SAMHD1 knockout 
mice [77]. Some—but not all—of the lentivectors used in 
(a)
(b) (c)
Fig. 3  Degradation of dNTPs by SAMHD1 controls reverse tran-
scription and may impact on other cellular processes. a Two alter-
native mechanisms by which SAMHD1 may inhibit reverse tran-
scription (RT) are indicated. (Left) SAMHD1 forms a tetramer [85, 
86, 192] that cleaves dNTPs—the substrates required for RT—into 
deoxyribonucleosides (dNs) and inorganic triphosphate (PPP). each 
monomer has an active site (white circle) and dGTP (or GTP [192, 
193]; black circles) is bound at an allosteric site. (Right) SAMHD1 
may also counteract reverse transcription by binding and/or degrad-
ing viral nucleic acids. b By lowering the intracellular dNTP concen-
tration ([dNTP] low), SAMHD1 not only restricts retroviruses (Rvs) 
but also DNA viruses and perhaps endogenous retroelements (Res). 
Moreover, balanced dNTP pools are likely to be required for accu-
rate DNA replication and DNA repair (green arrow). c Mutations 
in SAMHD1, which have been described in Aicardi-Goutières syn-
drome (AGS) and cancers such as chronic lymphocytic leukaemia, 
are predicted to disrupt the proteins’ catalytic function. As a result, 
dNTP concentrations in cells are elevated ([dNTP] high). This facili-
tates replication of retroviruses (Rvs), DNA viruses and possibly 
retroelements (Res). Detection of Res by the innate immune system 
could result in chronic production of type I interferons (IFN) trigger-
ing the onset of AGS [194]. Insertion of Res into new positions in 
the genome could also be a source of mutations leading to the devel-
opment of cancer. Moreover, imbalanced dNTP concentrations in the 
absence of functional SAMHD1 may impact on the fidelity of DNA 
replication and repair (red arrow) or on cell cycle progression, further 
promoting genome instability and transformation [195, 196]
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this study were controlled by SAMHD1 in the presence of 
a wild-type reverse transcriptase [77]. Much like what was 
discussed earlier for tetherin and MLv infection, these dif-
ferences perhaps relate to type I interferons that enhance 
SAMHD1 expression [76, 94]. Type I interferons are only 
induced by some lentivectors: second-generation vectors 
with a minimal genome do not induce type I interferons 
[64, 76], while first-generation vectors with a full genome 
do [64] [our own observations].
The observation that viruses bearing a polymerase 
with lower binding to nucleotides become increasingly 
sensitive to SAMHD1 strongly suggests that “dNTP 
starvation” is key to the mechanism by which SAMHD1 
restricts infection. Indeed, the reverse transcriptase 
v148I mutant virus was also attenuated in human cells, 
and this attenuation was partly relieved by vpx-mediated 
SAMHD1 degradation [72]. Moreover, SAMHD1 facili-
tates apoptosis in monocytes that is induced by infection 
with the delta-retrovirus human T cell leukaemia virus 
type 1 [95]. This effect can be reversed by provision of 
deoxyribonucleosides [95], again pointing to hydroly-
sis of dNTPs as the mechanism of SAMHD1’s antiviral 
activity. In short-term in vivo infection experiments using 
two different mouse gamma-retroviruses, Friend virus 
and M-MLv, virus replication and virus-induced pathol-
ogy were comparable in wild-type and SAMHD1-defi-
cient mice [76, 77]. Friend virus and M-MLv replicate in 
actively dividing lymphocytes. These cells contain large 
amounts of dNTPs needed to support genomic DNA 
replication. As such, the lack of SAMHD1-dependent 
restriction is likely due to dNTPs not being limiting for 
reverse transcription. In addition, posttranslational modi-
fication of SAMHD1 in cycling cells by phosphorylation 
has been suggested to inactivate its function to repress 
reverse transcription [88, 89, 96].
Our comparison of lentivectors bearing a wild-type and 
a mutant reverse transcriptase with reduced binding to 
dNTPs, and the finding that only the latter virus is potently 
controlled by SAMHD1 in vivo [76], also provide an 
explanation for the absence of a Vpx gene from the HIv-1 
genome: the high affinity of the HIv-1 reverse transcriptase 
for dNTPs may partially negate SAMHD1’s role in reduc-
ing intracellular dNTP concentrations. Indeed, although 
SAMHD1 potently restricts HIv-1 in cultured human cells, 
this effect is not absolute: typically, a small fraction of cells 
is infected in the presence of SAMHD1 [67, 68, 72]. Inter-
estingly, HIv-2’s reverse transcriptase is less efficient than 
HIv-1’s enzyme at low dNTP concentrations [97]. It, there-
fore, appears that these two closely related retroviruses use 
very different strategies: HIv-2 encodes vpx that targets 
SAMHD1 for degradation by the proteasome, while HIv-1 
evolved a reverse transcriptase with a low KM for dNTPs to 
partially evade the function of SAMHD1.
In this context, it is interesting to speculate that some 
degree of control exerted by SAMHD1 might actually be 
advantageous for HIv-1 at the level of an infected host—
by virtue of restricting the virus at the cellular level. Infec-
tion of dendritic cells with viruses, including HIv-2, is 
often a strong signal for dendritic cell activation [64, 98]. 
However, this is not the case during HIv-1 infection [64]. 
Degradation of SAMHD1 via experimental vpx delivery 
results in dendritic cell activation during HIv-1 infection 
and allows these cells to prime a T cell response [64]. In 
this setting, reverse transcribed cDNA is recognised by the 
recently identified cytosolic DNA sensor cGAS [99, 100] 
(for a review of the cGAS pathway, see [101]). In the pres-
ence of SAMHD1, the amount of reverse transcription 
products made in dendritic cells during HIv-1 infection 
is reduced due to low dNTP concentrations and possibly 
other mechanisms. This results in reduced cGAS stimu-
lation, dendritic cell activation and T-cell priming [100]. 
This is perhaps beneficial to HIv-1 and might explain why 
HIv-1 is more pathogenic than HIv-2 [100, 102]. Notably, 
the concept that cellular factors, which prevent the accumu-
lation of reverse transcribed cDNA, are advantageous for 
the virus in some settings by preventing the induction of an 
immune response had been proposed earlier in the context 
of TReX1 [103].
SAMHD1 is a conserved protein and orthologues have 
been identified in a variety of organisms, from marine 
invertebrates up to man [104]. This suggests that the evolu-
tionarily ancestral function of SAMHD1 may not be related 
to the control of lentiviruses. Indeed, several additional 
functions of SAMHD1 have been suggested (Fig. 3b, c):
Control of DNA viruses
Recent studies show that SAMHD1 also restricts DNA 
viruses, including herpesviruses and poxviruses [105, 
106]. A thymidine kinase-deficient vaccinia virus strain 
was more sensitive to SAMHD1 than the corresponding 
wild-type virus [106]. Thymidine kinase ensures the sup-
ply of dNTPs for viral genome replication. It is tempting to 
speculate that this viral enzyme has evolved as a SAMHD1 
antagonist and it will be interesting to test restriction of 
DNA viruses in vivo in SAMHD1 knockout mice.
Tumour suppression and prevention of autoimmune disease
Mutations in SAMHD1 have been identified in malig-
nant B-cells isolated from chronic lymphocytic leukaemia 
patients [107–109] and in other types of cancer [110–112]. 
Indeed, SAMHD1 has been suggested to be a tumour sup-
pressor [109, 113]. SAMHD1 is also one of the genes linked 
to Aicardi-Goutières syndrome, a hereditary autoinflam-
matory disease characterised by spontaneous and chronic 
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production of type I interferons [104, 114]. It is notewor-
thy that the ability of cells from Aicardi-Goutières syn-
drome patients with SAMHD1 mutations to control HIv-1 
is impaired [75, 115, 116].
Control of retroelements
A significant fraction of the human genome is composed 
of endogenous retroviruses and retrotransposons, collec-
tively called retroelements, and the same is true for most 
other sequenced genomes [117]. Two recent studies found 
that SAMHD1 prevents retro-transposition of retroele-
ment reporter constructs [85, 118]. It is, therefore, possible 
that SAMHD1 represses at least some retroelements, most 
likely by controlling their reverse transcription (Fig. 3b, c).
A function of SAMHD1 in suppressing reverse tran-
scription of endogenous retroviruses and retrotransposons 
may explain the role of SAMHD1 in cancer and autoim-
munity (Fig. 3b, c). Activation of retroelements in cells 
lacking functional SAMHD1 could result in mutations 
caused by insertions of retroelements into new sites in 
the genome. Moreover, detection of reverse transcribed 
cDNA by innate immune sensors may lead to the produc-
tion of type I interferons and ultimately Aicardi-Goutières 
syndrome [119]. These are exciting questions for future 
research that will benefit from the availability of SAMHD1-
deficient mice [76, 77, 91, 92].
APOBeC3 cytidine deaminases
The AID/APOBeC proteins are cytidine deaminases and 
convert cytosine to uracil in either DNA or RNA mole-
cules. They constitute a family of 11 members in humans 
and 5 in mice [120, 121]. The family can be divided into 
five subgroups: AID and APOBeC1-4 [120]. In mice, 
each subfamily has a single member, while in humans 
the APOBeC3 subfamily expanded and has 7 members 
called APOBeC3A-H [120]. The AID/APOBeC fam-
ily is characterised by the presence of one or two cytidine 
deaminase-like domains: AID, APOBeC1, -2, -3A/C/H 
and -4 have one cytidine deaminase-like domain, while 
APOBeC3B/D/F/G as well as mouse APOBeC3 have two 
such domains [120]. AID proteins introduce mutations into 
immunoglobulin genes and thereby contribute to antibody 
diversification [122]. APOBeC1 edits a specific messen-
ger RNA and changes its coding potential, while little is 
known about APOBeC2 and -4 [120, 121]. The APOBeC3 
subfamily and in some species APOBeC1 are involved in 
cell-intrinsic antiviral host defence and in the control of ret-
roelements [121, 123]. In particular, APOBeC3G has been 
studied in detail and can be considered as the first described 
HIv-1 restriction factor [4, 5, 123]. Several other members 
of the APOBeC3 subfamily have also been implicated in 
the restriction of HIv-1. Moreover, APOBeC3 proteins 
control other viruses including human T-cell leukaemia 
virus type 1 and hepatitis B virus. These findings have been 
summarised in a number of excellent review articles (for 
example, [4, 5, 121, 123–126]) and will not be discussed in 
detail here.
As was the case for tetherin and SAMHD1, the discovery 
of APOBeC3G as a restriction factor was helped by stud-
ies of an HIv-1 accessory gene: Vif. Indeed, the observation 
that vif protein was required for virus infectivity in some 
types of cells but was dispensable in other cells led to the 
identification of APOBeC3G as a cellular factor controlling 
HIv-1 in 2002 [127]. vif-deficient viruses can only replicate 
in cells that do not express APOBeC3G [127]. vif targets 
APOBeC3G for proteasomal degradation and may addition-
ally inhibit APOBeC3G expression or function [4, 5].
what is the mechanism by which APOBeC3G coun-
teracts HIv-1? APOBeC3G is packaged into virus par-
ticles, particularly in the absence of vif [4, 5]. As such, 
APOBeC3G is delivered into newly infected cells. 
APOBeC3G is associated with the viral core containing the 
viral RNA genome [4, 5]. This allows the protein to gain 
access to newly reverse transcribed cDNA. APOBeC3G 
converts cytosine to uracil in minus-sense single-stranded 
cDNA, causing extensive incorporation of deoxyadenosine 
instead of deoxyguanosine during plus-strand synthesis, 
which results in hypermutation of the viral genome [4, 5]. 
These G-to-A mutations in viral cDNA are believed to be 
deleterious to the virus [4, 5]. APOBeC3G also counteracts 
HIv-1 by additional mechanisms, for example by blocking 
translocation of reverse transcriptase (Fig. 4) [4, 5].
An antiviral role of APOBeC3G and related proteins 
in humans is supported by studies of virus hypermutation 
rates, APOBeC3 expression levels and sequence polymor-
phisms, and from analysis of how these correlate with clini-
cal parameters [128]. Here, I will summarise insights from 
experiments in mice, which have a single Apobec3 gene. 
Remarkably, the existence of a gene in mice called Rfv3 
that contributes to the immune response to Friend virus, 
particularly to virus-specific antibody production, had been 
noticed in the late 1970s [129, 130]. 30 years later, genetic 
mapping indicated that Rfv3 could correspond to the 
Apobec3 gene [131], which was then confirmed by genetic 
inactivation of Apobec3 in an Rfv3-resistant strain [132]. 
Alternative splicing of APOBeC3 pre-messenger RNA 
causes a Friend virus susceptible phenotype in some mouse 
strains [132, 133], suggestive of an important role for 
APOBeC3 in controlling retrovirus infection. Like human 
APOBeC3G, mouse APOBeC3 is packaged into retrovirus 
particles, including MMTv and MLv virions [134–136]. 
Mouse APOBeC3 can also incorporate into HIv-1 particles 
when it is overexpressed in human producer cells, although 
this is not antagonised by vif [137].
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Several studies tested the role of APOBeC3 in vivo by 
genetic ablation in the mouse [132, 134, 138, 139]. In one, 
a neomycin cassette was inserted into the Apobec3 locus 
by conventional gene targeting [138]. Three other stud-
ies generated APOBeC3-deficient animals using the same 
embryonic stem cell line, in which the Apobec3 gene had 
been disrupted by gene-trap technology [132, 134, 139]. 
APOBeC3-deficient mice develop normally and have no 
apparent phenotype [132, 134, 138]. Initial experiments, 
in which wild-type and knockout mice were challenged 
with retroviruses, demonstrated that APOBeC3 acts as a 
restriction factor in vivo. Indeed, MMTv replicates and 
spreads better in APOBeC3-deficient mice [134, 140]. 
Similarly, gamma-retroviruses, including Friend virus, 
M-MLv and LP-BM5, are controlled by APOBeC3 in 
vivo: these viruses replicate to higher titres in knockout 
mice and infection results in increased pathogenesis [132, 
141–143]. These studies also revealed that not only virion-
packaged APOBeC3 but also APOBeC3 expressed by 
the target cell contributes to virus restriction [142]. Fur-
thermore, restriction of exogenous retroviruses by mouse 
APOBeC3 appears to be largely independent of deamina-
tion [134, 135], despite the observation that the recombi-
nant protein possesses cytidine deaminase activity [136]. 
Instead, APOBeC3 restricts infection before or at the step 
of reverse transcription, although the exact mechanism 
remains to be determined [144, 145]. The deaminase activ-
ity of APOBeC3 plays perhaps a more important role in 
controlling endogenous retroviruses [146]. In contrast to 
the results obtained with retroviruses, in vivo replication 
of mouse gammaherpesvirus 68 is unaltered in APOBeC3 
knockout mice [139].
A series of further studies using APOBeC3-deficient 
mice revealed a number of interesting insights into the 
role of this restriction factor in controlling retrovirus 
infection in a living organism. In one set of experiments, 
the role of APOBeC3 in virus transmission was tested. 
Both vertical transmission of MMTv via milk and hori-
zontal, sexual transmission of LP-BM5 are controlled by 
APOBeC3 [143, 147]. In another set of studies, the impact 
of APOBeC3 on the development of an adaptive immune 
response during Friend virus infection was dissected. 
APOBeC3 was found to be required for the production of 
neutralising antibodies in vivo [132, 148, 149]. These data 
have been reviewed in detail elsewhere [150] and may be 
of relevance to the development of vaccines. An interesting 
mechanism of viral APOBeC3 inhibition was also revealed 
in the knockout mice. Many strains of MLv express a gly-
cosylated form of the viral gag protein called glycogag. 
Glycogag mutant viruses are attenuated in wild-type, but 
not in APOBeC3 knockout mice [151, 152]. Glycogag 
forms part of the virus capsid surrounding the viral genome 
and is required for capsid stability [151]. Glycogag may, 
therefore, prevent access of APOBeC3 and perhaps other 
cellular proteins to reverse transcribed cDNA [151]. This 
mechanism is distinct from the APOBeC3G antagonism 
exerted by HIv-1 vif that prevents packaging of the restric-
tion factor into virus particles [5]. It will be interesting to 
test whether the HIv-1 capsid has evolved to interfere with 
APOBeC3 proteins. It is noteworthy that the HIv capsid 
limits access of other host factors to viral nucleic acids and 
thereby prevents their detection by innate immune sensors, 
particularly cGAS [100, 153].
Several restriction factors are induced by type I interfer-
ons and proinflammatory stimuli such as lipopolysaccha-
ride (LPS). This includes the human APOBeC3 proteins 
[5] and also mouse APOBeC3, although in the latter case 
the level of induction by type I interferons appears to be 
weak [94, 154]. Administration of LPS or type I interferons 
blocks the replication of many viruses in vivo. Interestingly, 
the negative effect of LPS on MMTv replication in wild-
type mice was largely cancelled in APOBeC3-deficient 
animals [154]. Similarly, type I interferons failed to con-
trol Friend virus in APOBeC3 knockout mice [94]. A pos-
sible interpretation of these results is that APOBeC3 plays 
a particularly important and non-redundant role in in vivo 
control of these viruses [94, 154]. Indeed, a hierarchy of 
restriction factors had been suggested based on experiments 
using mice with higher cell surface expression of tetherin 
due to a polymorphism [43]. Interestingly, the effect of this 
polymorphism to decrease Friend virus replication can only 
be revealed in mice that have an alternatively spliced form 
Fig. 4  APOBeC3G introduces mutations into viral cDNA and pre-
vents reverse transcription. APOBeC3G (yellow star) is incorporated 
into virus particles during budding and is associated with the viral 
core. It is, therefore, delivered into newly infected cells. APOBeC3G 
directly inhibits reverse transcription, for example by blocking the 
progression of reverse transcriptase (violet square). APOBeC3G also 
deaminates cytosine to uracil in minus-sense single-stranded cDNA, 
causing extensive incorporation of deoxyadenosine instead of deoxy-
guanosine during plus-strand synthesis. This introduces mutations 
into the viral genome that can be deleterious, a process called hyper-
mutation
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of APOBeC3 linked to Friend virus susceptibility [43]. In 
the presence of the canonical Apobec3 allele that confers 
resistance to Friend virus, lower tetherin expression lev-
els did not relieve in vivo restriction, pointing to a degree 
of redundancy amongst restriction factors [43]. It will be 
interesting to test the virus susceptibility of mice lacking 
more than one restriction factor to determine how these 
proteins work together in vivo. The availability of tetherin-, 
SAMHD1- and APOBeC3-deficient animals opens the 
possibility of generating double and perhaps triple knock-
out mice. Moreover, it may be worthwhile to cross breed 
transgenic mice that express human proteins required for 
cellular entry and replication of HIv-1 (such as human 
CD4) [155] with animals that lack one or multiple restric-
tion factors. It is exciting to speculate that such mouse 
models will perhaps recapitulate some steps of the HIv-1 
life cycle.
Other restriction factors acting prior to integration
HIv-1 infection is controlled by a variety of other cellular 
proteins that can be classified as restriction factors based 
on their cell-intrinsic activities in blocking infection [156]. 
This includes several members of the TRIM protein fam-
ily, MOv10 and Mx2. These restriction factors will be dis-
cussed only briefly here, given the lack of in-depth in vivo 
studies in mouse knockout models.
TRIM5α has been characterised in detail and targets 
the capsid of HIv [5, 157]. TRIM5α lacks a clear ortho-
logue in mice (and as such will not be discussed further in 
this review), but it has been proposed that the Friend virus 
restriction factor Fv1 is similarly directed at retroviral cap-
sids [14]. Other TRIM proteins are also involved in the 
control of exogenous retroviruses and endogenous retroele-
ments, particularly in limiting transcription of integrated 
proviral DNA [158]. examples include TRIM28 (also 
known as KAP1) and TRIM24, and knockout mouse cells 
revealed a role of both proteins in controlling endogenous 
retroviruses [159, 160].
MOv10 and its paralogue MOv10L1 are helicase pro-
teins [161]. In vitro, MOv10 overexpression in HIv-1 or 
MLv producer cells results in reduced virus titres [162–
165]. As is the case for APOBeC3G, MOv10 is packaged 
into HIv-1 particles and, upon delivery into newly infected 
cells, inhibits infection by a mechanism that perhaps tar-
gets reverse transcription [163–166]. Interestingly, MOv10 
also controls endogenous retroelements [162, 167, 168]. 
MOv10 knockout mice have not been published; however, 
MOv10L1 has been targeted and mice lacking this helicase 
have a defect in controlling retrotransposons [169, 170]. 
This defect results in male infertility and a complete block 
of spermatogenesis due to increased activity of retrotrans-
posons in the male germ line [169, 170]. Mechanistically, 
MOv10L1 has been suggested to be involved in the piRNA 
pathway that controls retrotransposons [169–171].
Mx2 (also known as MxB) is a recently identified HIv-1 
restriction factor in human cells [172–175]. Mx2 is induced 
by type I interferons and is related to Mx1, an important 
restriction factor of influenza A virus [176]. Although the 
details of the mechanism by which Mx2 restricts HIv-1 are 
not fully understood, it appears that Mx2 targets a late post-
entry step, perhaps disrupting nuclear import of the reverse 
transcription complex [172–175]. Overexpression of 
human Mx2 in human cells has no or weak effects on MLv 
infection [172, 173]. whether mouse Mx2 controls retro-
viruses has not been tested. Commonly used inbred strains 
of mice lack functional Mx2 due to a mutation [177]. I will 
be interesting to repair this mutation or to introduce a func-
tional copy of the Mx2 gene [178] and to challenge such 
animals with retroviruses.
Intracellular HIV‑1 restriction after integration
Restriction factors exerting intracellular control of HIv-1 
after integration have not been studied in comparable detail 
as those restriction factors antagonising the virus before 
integration or at the membrane. Nevertheless, several host 
proteins targeting HIv-1 transcripts or the translation of 
viral proteins have been identified and will be briefly men-
tioned here.
RNase L was one of the first antiviral proteins to be dis-
covered [179]. In the absence of virus infection, RNase L 
is monomeric and inactive. Delivery of double-stranded 
RNA into cells during virus infection activates oligoad-
enylate synthase, which produces 2′-5′ oligoadenylates 
(2-5A). 2-5A binds RNase L resulting in dimerization 
and activation of its endonuclease activity. RNase L then 
degrades viral and host RNAs and thereby mediates an 
antiviral effect [179]. Several lines of in vitro data suggest 
that RNase L controls HIv-1 and Friend virus, perhaps by 
degrading viral transcripts [180–183]. Nevertheless, infec-
tion of RNase L knockout mice with Friend virus revealed 
that this factor is not required for the control of virus lev-
els and the induction of adaptive immune responses [183]. 
These observations highlight that retrovirus restriction 
in vitro does not always translate into virus control in an 
infected host and provide an example for the importance of 
in vivo studies.
ZAP (also known as ZC3HAv1) is a zinc finger protein 
that recognises retroviral RNA transcripts and targets them 
for degradation via the RNA exosome [184–186]. ZAP-
deficient mice have not been studied in retrovirus infec-
tion settings, but knockout cells support increased in vitro 




Another restriction factor acting after integration is 
SLFN11 [188, 189], a member of the Schlafen family of 
proteins that comprises 5 members in human and 10 in the 
mouse [190]. The expression of these proteins is induced 
by type I interferons and some family members have a 
described function in T-cells [190]. Overexpression of 
SLFN11 in virus producer cells results in lower HIv-1 
titres and this correlates with reduced levels of viral pro-
teins made by the producer cell [188]. Conversely, deple-
tion of this protein by RNA interference enhances viral 
titres and viral protein expression [188]. Interestingly, viral 
RNA levels are unaffected by SLFN11. Instead, SLFN11 
prevents viral protein expression at the level of translation. 
HIv-1 messenger RNAs have a bias in the use synonymous 
codons and often have A or U in the third position. This 
codon usage is suboptimal in mammalian cells due to the 
low abundance of cognate transfer RNAs. As such, viral 
messenger RNAs are translated inefficiently, and it appears 
that SLFN11 further decreases their translation. The pre-
cise mechanism is not fully understood, but it relates to the 
ability of SLFN11 to bind transfer RNAs [188]. This is pre-
dicted to further limit the availability of rare transfer RNAs, 
perhaps by sequestration or more indirectly by an impact 
on transfer RNA maturation or aminoacylation/deacylation 
[188]. The absence of a clear 1-to-1 orthologue of human 
SLFN11 in the mouse precludes direct knockout stud-
ies. The diversification of this protein family in different 
species might be related to a role in host defence against 
evolving pathogens, and further studies into antiviral func-
tions of these proteins are justified.
Conclusions and perspectives
Mouse knockout models have in several instances pro-
vided in vivo evidence for the antiviral activities of restric-
tion factors. valuable insights into the cell-intrinsic func-
tion and mechanism of action of virus restriction factors 
have been gained from studies in these animals or in cells 
derived from them. Moreover, mouse models led to inter-
esting insights into the biology of restriction factors in the 
context of virus infection—such as their impact on adap-
tive immune responses—and into their role in other settings 
such as autoimmunity. Therefore, it will be important to 
gene target more recently identified restriction factors that 
have not been studied in vivo yet (Table 1). It will also be 
interesting to generate new mouse lines that lack multiple 
restriction factors, or a restriction factor and another pro-
tein involved in the immune response to virus infection 
(such as a pattern recognition receptor) to test how these 
proteins work together in vivo.
Gene targeting has until recently been largely lim-
ited to the mouse that will certainly remain an important 
model in the years to come. New genome editing tools 
have become available in the last few years, including one 
based on the bacterial CRISPR-Cas9 system [1]. An excit-
ing development is the possibility to genetically modify 
monkeys with these tools [191]. As such, it is at least the-
oretically possible to generate knockout primates that lack 
a restriction factor. Such a model may provide the means 
to study lentivirus control by restriction factors in their 
natural hosts.
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